GSK plc 6-K, filed Jun 24, 2024
GSK plc (GSK)
6-K
2024-06-24
For: 2024-06-24
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on June 24, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued:
24 June 2024, London UK
GSK's Omjjara (momelotinib) approved in
Japan for treatment of myelofibrosis
●
Omjjara approved for use in both newly diagnosed or
previously treated myelofibrosis patients
●
Differentiated
mechanism of action addresses key manifestations of myelofibrosis,
namely anaemia, constitutional symptoms and
splenomegaly
GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of
Health, Labour and Welfare (MHLW) has
approved Omjjara (momelotinib) for the treatment of
myelofibrosis. Omjjara is a once-a-day, oral JAK1/JAK2 and activin
A receptor type 1 (ACVR1) inhibitor. The approval is based on data
from the pivotal phase III MOMENTUM and SIMPLIFY-1
trials.
This is the fourth major regulatory approval for GSK's momelotinib
in the treatment of myelofibrosis, following approval under the
brand name Ojjaara from the US Food and Drug Administration and
authorisations under the brand name Omjjara from the European Commission and the
Medicines and Healthcare products Regulatory Agency in the
UK.
Nina Mojas, Senior Vice President, Oncology Global Product
Strategy, GSK, said: "Myelofibrosis has a heavy
disease burden, with symptomatic patients experiencing spleen
enlargement, fatigue, night sweats and bone pain, along with
anaemia which can lead to treatment discontinuation and dependence
on regular blood transfusions. With the approval
of Omjjara, myelofibrosis
patients in Japan will have a new treatment option for this complex
blood cancer."
Myelofibrosis is a blood cancer that affects approximately 1 in
500,000 people worldwide, with up to 5,000 patients impacted in
Japan.[4],[5],[6] In
Japan, about 70% of patients diagnosed with primary myelofibrosis,
and about half of those patients diagnosed with secondary
myelofibrosis, have moderate to severe anaemia at the time of
diagnosis.1,2,3 Nearly
all patients are estimated to develop anaemia over the course of
the disease.[7],[8],[9],[10] Myelofibrosis
patients with anaemia require additional supportive care, including
transfusions, and more than 30% will discontinue treatment with
established therapies due to anaemia.[11] Patients
who are anaemic and transfusion dependent have a poor prognosis and
shortened survival.[12],[13],[14],[15],[16],[17],[18],[19],[20]
The approval is based on data from the MOMENTUM and SIMPLIFY-1
pivotal phase III trials. MOMENTUM was designed to evaluate the
safety and efficacy of momelotinib versus danazol for the treatment
and reduction of key manifestations of myelofibrosis in an anaemic,
symptomatic, JAK inhibitor-experienced population. SIMPLIFY-1 was
designed to evaluate the efficacy and safety of momelotinib versus
ruxolitinib in myelofibrosis patients who had not received a prior
JAK inhibitor therapy.
About Omjjara (momelotinib)
Momelotinib has a differentiated
mechanism of action, with inhibitory ability along three key
signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A
receptor, type I (ACVR1).1,[21],[22],[23] Inhibition
of JAK1 and JAK2 may improve constitutional symptoms and
splenomegaly.1,21,23 Additionally,
inhibition of ACVR1 leads to a decrease in circulating hepcidin
levels, potentially contributing to anaemia-related
benefit.1,21,22,23
In September 2023, the US Food and Drug
Administration licensed[24] momelotinib
under the brand name Ojjaara for
the treatment of intermediate or high-risk myelofibrosis, including
primary myelofibrosis or secondary myelofibrosis
(post-polycythaemia vera and post-essential thrombocythemia), in
adults with anaemia.
In January 2024, the European Commission granted
marketing authorisation[25] for Omjjara for
disease-related splenomegaly (enlarged spleen) or symptoms in adult
patients with moderate to severe anaemia who have primary
myelofibrosis, post polycythaemia vera myelofibrosis or post
essential thrombocythemia myelofibrosis and who are Janus kinase
(JAK) inhibitor naïve or have been treated with
ruxolitinib. Omjjara was
also approved[26] by
the Medicines and Healthcare products Regulatory Agency (MHRA) in
the United Kingdom to treat the symptoms experienced by adult
myelofibrosis patients who have moderate or severe
anaemia.
Please refer to the updated Product Information (PI) for
precautions concerning indication and important dosage,
administration, and safety information in Japan which will shortly
be updated at this link: Japan
Pharmaceuticals and Medical Devices Agency[27].
About myelofibrosis
Myelofibrosis is a rare blood cancer that disrupts
the body's normal production of blood cells because of dysregulated
JAK-signal transducer and activator of transcription protein
signalling. The clinical hallmarks of myelofibrosis are
splenomegaly (enlarged spleen), severely low blood counts,
including anaemia and thrombocytopenia, and debilitating
constitutional symptoms, such as fatigue, night sweats and bone
pain, attributable to ineffective haematopoiesis and excessive
production of proinflammatory cytokines.[28],[29]
About the pivotal clinical trials
MOMENTUM was a phase III, global, multicentre,
randomised, double-blind study investigating momelotinib versus
danazol in patients (n=195) with myelofibrosis who were symptomatic
and anaemic and had been previously treated with a licensed JAK
inhibitor. The trial was designed to evaluate the safety and
efficacy of momelotinib for treating and reducing key hallmarks of
the disease: symptoms, blood transfusions (due to anaemia) and
splenomegaly. The MOMENTUM trial met all its primary and key
secondary endpoints, demonstrating statistically significant
response with respect to constitutional symptoms, splenic reduction
and transfusion independence in patients treated with momelotinib
versus danazol (Total Symptom Score reduction of 50% or greater:
25% momelotinib, 9% danazol, p=0.0095; reduction of spleen volume
by 35% or greater: momelotinib 22%, danazol 3%, p=0.0011; no
transfusions and all haemoglobin values ≥8 g/dL in the 12
weeks prior to week 24: momelotinib 30%, danazol
20%).[30] The
most common non-haematological treatment-emergent adverse events in
momelotinib-treated patients over the entire study period as of the
data cutoff were diarrhoea (45 [26%] of 171) and asthenia (28
[16%]); the most common grades 3 and 4 treatment-emergent adverse
events were thrombocytopenia (33 [19%]) and anaemia (19
[11%]).[31] Results
from the 24-week randomised treatment period were presented at the
2022 American Society of Clinical Oncology (ASCO) Annual Meeting
and subsequently published in The Lancet,[32],[33] with
48-week data presented at the 64th American Society of Hematology
(ASH) Annual Meeting and Exposition in December 2022 and
subsequently published in The Lancet
Hematology.31,[34]
SIMPLIFY-1 was a multicentre randomised, double-blind, phase III
study that compared the safety and efficacy of momelotinib to
ruxolitinib in patients with myelofibrosis who had not received
prior treatment with a JAK inhibitor (momelotinib: n=215 and
ruxolitinib: n=217). SIMPLIFY-1 met its primary endpoint,
demonstrating non-inferiority of momelotinib to ruxolitinib in
spleen volume response (reduction by 35% or greater) with a
difference of 9% (95% CI 2%-16%), and substantial improvements in
transfusion independence rates (66.5% for momelotinib compared to
49.3% for ruxolitinib), a difference of 18% (95% CI
9%-26%).[35],[36] The
most common grade 3 or higher haematologic abnormalities in either
group were thrombocytopenia and anaemia. Grade 3 or higher
infections occurred in 7% of patients who received momelotinib and
3% of patients who received ruxolitinib.[37]
GSK in oncology
GSK
is committed to maximising patient survival through
transformational medicines, with a current focus on breakthroughs
in immuno-oncology and tumour-cell targeting therapies, and
development in haematologic malignancies, gynaecologic cancers, and
other solid tumours.
About GSK
GSK
is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madison
Goring
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540 742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Camilla
Campbell
|
+44 (0)
7803 050238
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q1 Results for 2024.
Registered
in England & Wales:
No.
3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
[1] Chifotides, HT, Bose, P, Verstovsek, S.
Momelotinib: an emerging treatment for myelofibrosis patients with
anemia. J Hematol
Oncol.
2022;15(7):1-18.
[2] Shide K et al. Nationwide prospective survey of
secondary myelofibrosis in Japan: superiority of DIPSS-plus to
MYSEC-PM as a survival risk model. Blood Cancer
J. 2023;13(1):110. doi:
10.1038/s41408-023-00869-9
[3] Kirito K et al. Int J
Hematol. 2018;107(1):92-97.
[4] Orphanet. Primary Myelofibrosis. 2019. Accessed
01 February 2023. https://www.orpha.net
[5] Takenaka K et al., Clinical features and outcomes
of patients with primary myelofibrosis in Japan: report of a
17-year nationwide survey by the Idiopathic Disorders of
Hematopoietic Organs Research Committee of
Japan. Int J
Hematol. 2017
Jan;105(1):59-69. doi:
10.1007/s12185-016-2102-3
[6] Myelofibrosis - Epidemiology Forecast -
2032. DelveInsight. 2022;1-60.
[7] Tefferi A, Lasho TL, Jimma T, et
al. One thousand patients with primary myelofibrosis:
the mayo clinic experience. Mayo Clin
Proc. 2012;87(1):25-33.
doi:10.1016/j.mayocp.2011.11.001
[8] Bose P, et al. Curr Hematol Malign
Rep. 2018;13:164-172. doi:
https://doi.org/10.3109/10428194.2013.813500
[9] Scherber, RM, Mesa, R. Management of challenging
myelofibrosis after JAK inhibitor failure and/or
progression. Blood Rev. 2020;42:100716.
https://doi.org/10.1016/j.blre.2020.100716
[10] Bassiony S, Harrison CN, McLornan DP. Evaluating
the Safety, Efficacy, and Therapeutic Potential of Momelotinib in
the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to
Date. Ther Clin Risk
Manag. 2020;16:889-901.
Published 2020 Sep 25. doi:10.2147/TCRM.S258704
[11] Kuykendall AT, Shah S, Talati C, et al. Between a
rux and a hard place: evaluating salvage treatment and outcomes in
myelofibrosis after ruxolitinib
discontinuation. Ann
Hematol.
2018;97(3):435-441.
[12] Naymagon, L., Mascarenhas, J.
Myelofibrosis-Related Anemia: Current and Emerging Therapeutic
Strategies. HemaSphere. 2017;1(1):e1. doi:
10.1097/HS9.0000000000000001
[13] How J, Hobbs GS. A Practical Guide for Using
Myelofibrosis Prognostic Models in the Clinic. J Natl Compr Canc
Netw. 2020;18(9):1271-1278.
https://doi.org/10.6004/jnccn.2020.7557
[14] Nicolosi M, et al. Sex and degree of severity influence the
prognostic impact of anemia in primary myelofibrosis: analysis
based on 1109 consecutive patients. Leukemia. 2018;32(5):1254-1258.
https://doi.org/10.1038/s41375-018-0028-x
[15] Tefferi A, et al. Use of the Functional Assessment of Cancer
Therapy--anemia in persons with myeloproliferative
neoplasm-associated myelofibrosis and
anemia. Clin Ther. 2014;36(4):560-566.
[16] Tefferi A. Primary myelofibrosis: 2021 update on
diagnosis, risk-stratification and management. Am J
Hematol. 2021;96(1):145-162.
https://doi.org/10.1002/ajh.26050
[17] Rumi E, et al. The Genetic Basis of Primary Myelofibrosis and
Its Clinical Relevance. Int J Mol
Sci. 2020;21(23):8885.
https://doi.org/10.3390/ijms21238885
[18] QxMD. DIPSS prognosis in myelofibrosis. Accessed
September 12, 2022.
https://qxmd.com/calculate/calculator_187/dipss-prognosis-in-myelofibrosis.
[19] QxMD. DIPSS plus score for prognosis of
myelofibrosis. Accessed September 12, 2022.
[20] Elena C, et al. Red blood cell
transfusion-dependency implies a poor survival in primary
myelofibrosis irrespective of IPSS and
DIPSS. Haematologica.
2011;96(1):167-170.
https://doi.org/10.3324/haematol.2010.031831.
[21] Verstovsek S, et al. MOMENTUM: momelotinib vs
danazol in patients with myelofibrosis previously treated with JAKi
who are symptomatic and anemic. Future
Oncol.
2021;17(12):1449-1458.
[22] Asshoff M, et al. Momelotinib inhibits ACVR1/ALK2, decreases
hepcidin production, and ameliorates anemia of chronic disease in
rodents. Blood. 2017;129(13):1823-1830.
[23] Oh S, et al. ACVR1/JAK1/JAK2 inhibitor
momelotinib reverses transfusion dependency and suppresses hepcidin
in myelofibrosis phase 2 trial. Blood Adv. 2020;4(18):4282-4291.
[24] GSK press release issued 15 September 2023:
Ojjaara (momelotinib) approved in the US as the first and only
treatment indicated for myelofibrosis patients with
anaemia. Available at
https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/
[25] GSK press release issued 29 January 2024:
European Commission authorises GSK's Omjjara (momelotinib).
Available at
https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-omjjara-momelotinib/
[26] MHRA press release issued 31 January
2024: Omjjara licensed for anaemic myelofibrosis patients
to treat the symptoms of their disease. Available at
https://www.gov.uk/government/news/omjjara-licensed-for-anaemic-myelofibrosis-patients-to-treat-the-symptoms-of-their-disease
[27] Japan Pharmaceuticals and Medical Devices Agency
website:
https://www.info.pmda.go.jp/psearch/html/menu_tenpu_base.html.
[28] Atallah E, Verstovsek S. Emerging drugs for
myelofibrosis. Expert Opin Emerg Drugs. 2012 Dec;17(4):555-70. doi:
10.1517/14728214.2012.748748. PMID: 23186315; PMCID:
PMC5009610.
[29] MPN Research Foundation. Primary Myelofibrosis
(PMF). 2021. Accessed August 2022.
http://www.mpnresearchfoundation.org/primary-myelofibrosis-pmf/
[30] Verstovsek S, et al. MOMENTUM: momelotinib vs
danazol in patients with myelofibrosis previously treated with JAKi
who are symptomatic and anemic. Future
Oncol.
2021;17(12):1449-1458.
[31] Gerds AT, et
al. Momelotinib versus danazol in
symptomatic patients with anaemia and myelofibrosis previously
treated with a JAK inhibitor (MOMENTUM): an updated analysis of an
international, double-blind, randomised phase 3
study. The Lancet
Haematology. 2023;10(9):E735-E746.
https://doi.org/10.1016/S2352-3026(23)00174-6.
[32] Verstovsek S, et al. Momelotinib versus danazol
in symptomatic patients with anaemia and myelofibrosis (MOMENTUM):
results from an international, double-blind, randomised,
controlled, phase 3 study. The Lancet. 2023;401(10373):269-280.
[33] Mesa R, et al. Presented at: American Society of
Clinical Oncology; June 2022. Abstract 7002.
[34] Gerds AT, et al. Presented at: American Society
of Hematology; December 2022. Abstract 627.
[35] Mesa R, et al. Presented at: ISPOR
2021.
[36] Mesa R, et al. Presented at: SOHO 2021. Poster
MPN-303.
[37] Mesa RA, Kiladjian JJ, Catalano JV, Devos T,
Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W,
Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: A Phase
III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus
Kinase Inhibitor-Naïve Patients With Myelofibrosis. J Clin
Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418.
Epub 2017 Sep 20. PMID: 28930494; PMCID:
PMC6553796.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
24, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|